ClinicalTrials.gg
CompletedNCT00537082Updated Apr 21, 2011Results posted

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

A Phase 2 interventional study of FTY720 and Placebo in Multiple Sclerosis, sponsored by Novartis. Completed at 18 sites in Japan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2011-04-21.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
17th of 34
171 · median 167
Started
2007
the only one that year
Phase 2
4 of 34
none open now
Registered
5th of 34
by date
Lead sponsor
10 of 34
Novartis

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 17th largest by enrollment, is the only one that started in 2007, is one of 4 in phase 2, and was the 5th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • FTY720,
  • MS
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 18-60
  • Patients with a diagnosis of multiple sclerosis

Exclusion criteria

Exclusion Criteria:

  • Patients with a history or presence of chronic disease of the immune system other than MS
  • Patients with a history or presence of , pulmonary or heart disease, etc.
  • Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    FTY720 0.5 mg

    FTY720

    Drug: FTY720

  • Experimental
    FTY720 1.25 mg

    FTY720

    Drug: FTY720

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugFTY720

    Administered orally once daily for 6 months

  • DrugPlacebo

    Administered orally once daily for 6 months

06

What researchers measure

Primary outcomes

  1. Number of Patients Free of Gadolinium-enhanced T1-Weighted Magnetic Resonance Imaging (MRI) Lesions at Both Month 3 and Month 6

    Brain Magnetic Resonance Imaging (MRI) was performed at Month 3 and Month 6. Gadolinium-enhancing lesions (active lesions) represent acute inflammatory activity only and dissipate within 2-8 weeks of appearance. MRI scans were analyzed by blinded readers at the central MRI Evaluation Center to ensure consistency. Any Gd-enhanced T1 weighted MRI data obtained less than 14 days after the steroid used to treat MS relapses is invalid and excluded.

    Time frame: Month 3 and Month 6

Secondary outcomes

  1. Number of Patients Free of MS Relapse up to Month 6 (Confirmed Relapse Only)

    A relapse must have been confirmed by a neurologist and was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS).

    Time frame: up to Month 6

  2. Number of Patients Free of New or Newly Enlarged T2 Lesions

    The number of T2 lesions were obtained from MRI scans at Screening visit. The numbers of new/newly enlarging T2 lesions were obtained from MRI scans at Month 3 or more. New lesions were identified by comparing each lesion already seen in previous examinations. Lesions expanding throughout several slices were counted as only one lesion.

    Time frame: up to Month 3 and up to Month 6

  3. Annualized Relapse Rate (ARR) at 6 Months

    Annualized relapse rate (ARR) of the treatment group is calculated by taking the total number of confirmed relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate.

    Time frame: 6 Months

07

Results

Posted Mar 23, 2011

Participant flow

Participant flow — Overall Study
MilestoneFTY720 1.25 mgFTY720 0.5 mgPlacebo
Started575757
Completed484851
Not completed996
Withdrew: Adverse event663
Withdrew: Protocol violation021
Withdrew: Lack of efficacy002
Withdrew: Withdrawal by subject010
Withdrew: Discontinued before initiating treatment300

Outcome measures

PrimaryNumber of Patients Free of Gadolinium-enhanced T1-Weighted Magnetic Resonance Imaging (MRI) Lesions at Both Month 3 and Month 6

Brain Magnetic Resonance Imaging (MRI) was performed at Month 3 and Month 6. Gadolinium-enhancing lesions (active lesions) represent acute inflammatory activity only and dissipate within 2-8 weeks of appearance. MRI scans were analyzed by blinded readers at the central MRI Evaluation Center to ensure consistency. Any Gd-enhanced T1 weighted MRI data obtained less than 14 days after the steroid used to treat MS relapses is invalid and excluded.

Time frame:
Month 3 and Month 6
Reported as:
Number · Participants
Number of Patients Free of Gadolinium-enhanced T1-Weighted Magnetic Resonance Imaging (MRI) Lesions at Both Month 3 and Month 6
ParticipantsFTY720 1.25 mgFTY720 0.5 mgPlacebo
Number of Patients Free of Gadolinium-enhanced T1-Weighted Magnetic Resonance Imaging (MRI) Lesions at Both Month 3 and Month 6433521
SecondaryNumber of Patients Free of MS Relapse up to Month 6 (Confirmed Relapse Only)

A relapse must have been confirmed by a neurologist and was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS).

Time frame:
up to Month 6
Reported as:
Number · Participants
Number of Patients Free of MS Relapse up to Month 6 (Confirmed Relapse Only)
ParticipantsFTY720 1.25 mgFTY720 0.5 mgPlacebo
Number of Patients Free of MS Relapse up to Month 6 (Confirmed Relapse Only)454537
SecondaryNumber of Patients Free of New or Newly Enlarged T2 Lesions

The number of T2 lesions were obtained from MRI scans at Screening visit. The numbers of new/newly enlarging T2 lesions were obtained from MRI scans at Month 3 or more. New lesions were identified by comparing each lesion already seen in previous examinations. Lesions expanding throughout several slices were counted as only one lesion.

Time frame:
up to Month 3 and up to Month 6
Reported as:
Number · Participants
Number of Patients Free of New or Newly Enlarged T2 Lesions
ParticipantsFTY720 1.25 mgFTY720 0.5 mgPlacebo
Month 3 (n = 50, 49, 51)303423
Month 6 (n = 48, 48, 50)283118
SecondaryAnnualized Relapse Rate (ARR) at 6 Months

Annualized relapse rate (ARR) of the treatment group is calculated by taking the total number of confirmed relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate.

Time frame:
6 Months
Reported as:
Number · Relapses per year
Annualized Relapse Rate (ARR) at 6 Months
Relapses per yearFTY720 1.25 mgFTY720 0.5 mgPlacebo
Annualized Relapse Rate (ARR) at 6 Months0.4070.5121.131

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FTY720 1.25mg—11/54 (20.4%)42/54 (77.8%)
FTY720 0.5mg—5/57 (8.8%)41/57 (71.9%)
Placebo—3/57 (5.3%)27/57 (47.4%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventFTY720 1.25mgFTY720 0.5mgPlacebo
BradycardiaCardiac disorders8/543/570/57
Atrioventricular block second degreeCardiac disorders2/540/570/57
Sinus bradycardiaCardiac disorders1/540/570/57
Heart rate decreasedInvestigations1/540/570/57
Liver function test abnormalInvestigations1/540/570/57
Facial palsyNervous system disorders1/540/570/57
Multiple sclerosis relapseNervous system disorders1/540/570/57
HypotensionVascular disorders1/540/570/57
Atrioventricular block first degreeCardiac disorders0/541/570/57
Stress cardiomyopathyCardiac disorders0/540/571/57
Most frequent other events
Showing 10 of 16
Most frequent other events
EventFTY720 1.25mgFTY720 0.5mgPlacebo
NasopharyngitisInfections and infestations21/5424/5719/57
Liver function test abnormalInvestigations18/5412/573/57
DiarrhoeaGastrointestinal disorders6/543/573/57
NauseaGastrointestinal disorders5/544/572/57
HeadacheNervous system disorders5/545/574/57
ConstipationGastrointestinal disorders2/544/571/57
PyrexiaGeneral disorders2/542/574/57
DizzinessNervous system disorders3/544/571/57
LeukopeniaBlood and lymphatic system disorders3/541/570/57
LymphopeniaBlood and lymphatic system disorders3/541/570/57

Baseline characteristics

Age Continuous
Age Continuous(years)FTY720 1.25 mgFTY720 0.5 mgPlaceboTotal
Mean36.0 ± 9.3135.0 ± 9.0135.0 ± 8.9335.3 ± 9.04
Sex: Female, Male
Sex: Female, Male(Participants)FTY720 1.25 mgFTY720 0.5 mgPlaceboTotal
Female394039118
Male18171853
Region of Enrollment
Region of Enrollment(participants)FTY720 1.25 mgFTY720 0.5 mgPlaceboTotal
Japan575757171
08

Study locations

18 sites
  • Novartis Investigative site
    Sapporo-shi, Hokkaido, Japan
  • Novartis Investigative Site
    Chiba, 276-8524, Japan
  • Novartis Investigative Site
    Ehime, 791-0295, Japan
  • Novartis Investigative Site
    Fukuoka, 807-8555, Japan
  • Novartis Investigative Site
    Gunma, 371-8511, Japan
  • Novartis Investigative Site
    Hyogo, 650-0017, Japan
  • Novartis Investigative Site
    Ibaraki, 305-8576, Japan
  • Novartis
    Iwate, 020-8505, Japan
  • Novartis Investigative Site
    Kanagawa, 259-1193, Japan
  • Novartis Investigative Site
    Kyoto, 604-8453, Japan
  • Novartis Investigative Site
    Kyoto, 616-8255, Japan
  • Novartis Investigative Site
    Niigata, 951-8520, Japan
  • Novartis Investigative Site
    Osaka, 556-0016, Japan
  • Novartis Investigative Site
    Osaka, 589-8511, Japan
  • Novartis Investigative Site
    Tochigi, 329-0498, Japan
  • Novartis Investigative Site
    Tokyo, 145-0065, Japan
  • Novartis Investigative Site
    Tokyo, 162-8666, Japan
  • Novartis Investigative Site
    Wakayama, 641-8510, Japan
09

References and documents

Publications

  • Saida T, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Ueda K, Auberson LZ, Tsumiyama I, Nagato K, Kira JI. Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study. BMC Neurol. 2017 Jan 28;17(1):17. doi: 10.1186/s12883-017-0794-5. PubMed 28129749 ↗
  • Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, Tang D, Zhang-Auberson L, Kira J. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler. 2012 Sep;18(9):1269-77. doi: 10.1177/1352458511435984. Epub 2012 Feb 21. PubMed 22354739 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007 and a primary completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2007
First posted
Sep 28, 2007
Start
Sep 2007
Primary completionActual
Feb 2010
Results first posted
Mar 23, 2011
Last update
Apr 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00537082
Lead sponsor
Novartis
First posted
Sep 28, 2007
Start date
Sep 2007
Primary completion
Feb 2010
Results posted
Mar 23, 2011
Last update
Apr 21, 2011

Study contacts

Novartis Pharmaceuticals, Japan
principal investigator · +81 3 3797 8748
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion